Disease · MONDO_0018456

polyarticular juvenile idiopathic arthritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. polyarticular juvenile idiopathic arthritis. Diseases, record MONDO_0018456. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018456

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: polyarticular juvenile idiopathic arthritis; Open Targets
Open Targets ID: MONDO_0018456; Open Targets
Other names: juvenile polyarthritis, juvenile polyarticular arthritis, polyarticular JIA; Open Targets
Orphanet: ORPHA:404580; Orphanet
Highest stage of its drugs: Phase 3, for 7 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 3	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 3	https://conductscience.org/library/genes/942	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 3	https://conductscience.org/library/genes/3570	Drugs and targets
JAK3	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets
TYK2	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03773978	A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis	Phase 3	220	2022-10-07	Juvenile Idiopathic Arthritis	BARICITINIB	Its record names the disease	ClinicalTrials.gov
NCT01904279	A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)	Phase 1	52	2017-03-16	Juvenile Idiopathic Arthritis	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06654882	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis	Phase 3	400		Polyarticular Course Juvenile Idiopathic Arthritis (JIA)	ABATACEPT, TOCILIZUMAB, TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT03728478	STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS	Phase 3	260		Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative	ETANERCEPT, METHOTREXATE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT02165345	Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis	Phase 1	82		Juvenile Idiopathic Arthritis	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00144625	Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	Phase 3	19		Polyarticular Juvenile Idiopathic Arthritis	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
TCZ SC 162 mg Q3W vs TCZ SC 162 mg Q2W: serious adverse events	1 of 27	2 of 25	52	NCT01904279

Source Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40915298	DERIVED	1	PubMed
38552315	DERIVED	1	PubMed
38334147	DERIVED	1	PubMed
37423231	DERIVED	1	PubMed
36071444	DERIVED	1	PubMed
33506875	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018456

GET https://conductscience.org/api/diseases/v1/MONDO_0018456/drugs

API reference For AI assistants